Followers | 72 |
Posts | 4228 |
Boards Moderated | 2 |
Alias Born | 08/21/2015 |
Monday, April 26, 2021 2:40:54 PM
A Study to Assess 18-Methoxycoronaridine
https://www.clinicaltrials.gov/ct2/show/NCT04292197?lead=Mind+Medicine%2C+Inc.&lead_ex=Y&draw=2&rank=1
The current contact for this trial is listed as:
Rob Barrow... he replaced the contacts below who were originally listed on the Trial Data when this PR dropped on Feb. 2, 2021... which makes sense since he is the Business Development Officer:
https://www.prnewswire.com/news-releases/mindmed-streamlines-leadership-with-further-emphasis-on-integrating-psychedelic-drug-development-with-digital-medicines-and-therapeutics-301219840.html
---
The ORIGINAL contacts on this trial work for Janssen Pharmaceutical Companies were:
Jason Summa - https://www.linkedin.com/in/jasonsumma/Jamie Freedman - https://www.linkedin.com/in/jamie-freedman-0543104/
You can proof this by looking at the revision history of the Trial... Look at Version 5 of the document.
https://www.clinicaltrials.gov/ct2/history/NCT04292197?V_5=View#StudyPageTop
Both of these folks are tied to Johnson & Johnson via Janssen... I don't think that is a coincidence.
They are working with Linear Clinical Research Ltd in Australia / Perth. According to the website:
Australian (TGA) clinical trial start-ups are typically 4-6 months faster than US (FDA) trials. Better still, they’re much cheaper – often a third of the cost and exceptional quality.
No IND required
Fast-tracked approvals
Generous R&D refunds
Excellent health system Access to patient databases
Data accepted by FDA, EMA, CFDA & PDMA
---
Looks like to me they will fast track in Australia - then partner with J&J if successful.
Recent MNMD News
- MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York • Business Wire • 05/04/2024 12:00:00 PM
- MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update • Business Wire • 05/02/2024 11:00:00 AM
- MindMed to Present at Upcoming May Medical Conferences • Business Wire • 04/25/2024 11:00:00 AM
- MindMed to Present at Upcoming April Medical Conferences • Business Wire • 04/02/2024 11:00:00 AM
- MindMed Announces Voluntary Delisting from Cboe Canada • Business Wire • 04/01/2024 09:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 12:32:03 PM
- MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference • Business Wire • 03/11/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 01:19:43 PM
- Mind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private Placement • Business Wire • 03/07/2024 12:13:00 PM
- Form S-3MEF - Registration adding securities to prior Form S-3 registration [Rule 462(b)] • Edgar (US Regulatory) • 03/07/2024 12:09:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:56:00 AM
- MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder • Business Wire • 03/07/2024 11:00:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/01/2024 06:56:37 PM
- MindMed to Host Conference Call and Webcast to Discuss Data Update for MM120 • Business Wire • 03/01/2024 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 09:45:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 09:45:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 09:45:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 09:45:16 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/28/2024 12:20:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 12:15:11 PM
- MindMed Reports 2023 Financial Results and Business Updates • Business Wire • 02/28/2024 12:05:00 PM
- MindMed to Host Conference Call and Webcast to Discuss 2023 Financial Results and Provide Business Update • Business Wire • 02/22/2024 12:00:00 PM
- MindMed to Participate in the 34th Annual Oppenheimer Healthcare Life Sciences Conference • Business Wire • 02/07/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 01:00:24 PM
- MindMed Announces Business Update and Anticipated Milestones for 2024 • Business Wire • 01/08/2024 12:45:00 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM